A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study

被引:74
作者
Tang, Xin [1 ,2 ]
Zhou, Xiaojuan [1 ,2 ]
Li, Yanying [1 ,2 ]
Tian, Xue [1 ,2 ]
Wang, Yongsheng [1 ,2 ]
Huang, Meijuan [1 ,2 ]
Ren, Li [1 ,2 ]
Zhou, Lin [1 ,2 ]
Ding, Zhenyu [1 ,2 ]
Zhu, Jiang [1 ,2 ]
Xu, Yong [1 ,2 ]
Peng, Feng [1 ,2 ]
Wang, Jin [1 ,2 ]
Lu, You [1 ,2 ]
Gong, Youling [1 ,2 ]
机构
[1] Sichuan Univ, Dept Thorac Oncol, Canc Ctr, West China Hosp, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, State Key Lab Biotherapy, Canc Ctr, West China Hosp, Chengdu, Sichuan, Peoples R China
关键词
PHASE-II; LOCAL THERAPY; CHEMOTHERAPY; RADIOTHERAPY; RADIATION; DOCETAXEL;
D O I
10.1245/s10434-018-6929-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic esophageal cancer (mEC) is the end stage of esophageal cancer. We aimed to construct a predictive model predicting the cancer-specific survival (CSS) of mEC patients. Data from 1917 patients with initially diagnosed mEC were extracted from the Surveillance, Epidemiology, and End Results database between 2010 and 2015. Patients were randomly divided into the training and validation cohorts (7:3). Cox regression was conducted to select the predictors of CSS. The validation of the nomogram was performed using concordance index (C-index), calibration curves, and decision curve analyses (DCAs). Cancer-specific death occurred in 1559/1917 (81.3%) cases. Multivariate Cox regression indicated that factors including age, sex, grade at diagnosis, number of metastatic organs at diagnosis, pathological type, local treatment, and chemotherapy were independent predictors of CSS. Based on these factors, a predictive model was built and virtualized by nomogram. The C-index of the nomogram was 0.762. The calibration curves showed good consistency of CSS between the actual observation and the nomogram prediction, and the DCA showed great clinical usefulness of the nomogram. A risk classification system was built that could perfectly classify mEC patients into three risk groups. In the total cohort, the median CSS of patients in the low-, intermediate- and high-risk groups was 11.0 months (95% confidence interval [CI] 10.1-11.9), 8.0 months (95% CI 7.3-8.7), and 2.0 months (95% CI 1.8-2.2), respectively. We constructed a nomogram and a corresponding risk classification system predicting the CSS of patients with initially diagnosed mEC. These tools can assist in patient counseling and guiding treatment decision making.
引用
收藏
页码:321 / 328
页数:8
相关论文
共 27 条
  • [1] Patterns of distant organ metastases in esophageal cancer: a population-based study
    Ai, Dashan
    Zhu, Hanting
    Ren, Wenjia
    Chen, Yun
    Liu, Qi
    Deng, Jiaying
    Ye, Jinjun
    Fan, Jianhong
    Zhao, Kuaile
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 (09) : 3023 - 3030
  • [2] Impact of Chemotherapy on Quality of Life in Patients With Metastatic Esophagogastric Cancer
    Al-Batran, Salah-Eddin
    Ajani, Jaffer A.
    [J]. CANCER, 2010, 116 (11) : 2511 - 2518
  • [3] Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer
    Albertsson, M.
    Johansson, B.
    Friesland, S.
    Kadar, L.
    Letocha, H.
    Frykholm, G.
    Wagenius, G.
    [J]. MEDICAL ONCOLOGY, 2007, 24 (04) : 407 - 412
  • [4] [Anonymous], 2018, NCCN guidelines version 1.2018 invasive breast cancer: NCCN evidence blocks
  • [5] A reliable risk score for stage IV esophagogastric cancer
    Blank, S.
    Lordick, F.
    Dobritz, M.
    Grenacher, L.
    Burian, M.
    Langer, R.
    Roth, W.
    Schaible, A.
    Becker, K.
    Blaeker, H.
    Sisic, L.
    Stange, A.
    Compani, P.
    Schulze-Bergkamen, H.
    Jaeger, D.
    Buechler, M.
    Siewert, J. R.
    Ott, K.
    [J]. EJSO, 2013, 39 (08): : 823 - 830
  • [6] Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer
    Bleiberg, H
    Conroy, T
    Paillot, B
    Lacave, AJ
    Blijham, G
    Jacob, JH
    Bedenne, L
    Namer, M
    DeBesi, P
    Gay, F
    Collette, L
    Sahmoud, T
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (08) : 1216 - 1220
  • [7] Optimal Timing of Early Versus Delayed Radiotherapy for Inoperable Stage IV Esophageal Cancer
    Chen, Y.
    Liu, Y.
    Cheng, X.
    Ke, S.
    Shi, W.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E140 - E141
  • [8] Upfront Esophageal Radiation and Chemotherapy is Associated With Improved Overall Survival Compared to Chemotherapy Alone for Metastatic Esophageal Cancer
    De, B.
    Rhome, R. M.
    Doucette, J.
    Buckstein, M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E143 - E143
  • [9] Enzinger PC, 1999, SEMIN ONCOL, V26, P12
  • [10] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Dikshit, Rajesh
    Eser, Sultan
    Mathers, Colin
    Rebelo, Marise
    Parkin, Donald Maxwell
    Forman, David
    Bray, Freddie
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) : E359 - E386